Approach and progress

Materiality Assessment

During 2023, medmix conducted a materiality assessment to identify and assess the potential environmental, social, employee-related, human rights and combatting corruption topics that could affect the company’s business performance.

The assessment was performed in accordance with the requirements of the Swiss Code of Obligations and the reporting standard of the Global Reporting Initiative (GRI).

The following steps were taken during the assessment process:

As a result of the assessment, medmix identified six material issues, covering the 14 most relevant topics, and in line with the Sustainability Strategy:

Presentation of concepts

Business Code of Conduct

medmix is committed to preventing corruption and has a zero-tolerance policy towards corrupt practices. We have developed controls to mitigate the risk of corruption, such as the implementation of our Business Code of Conduct, the Anti-Corruption Directive, the Healthcare Compliance Directive and our Delegation of Authority Directive. We have established a system for monitoring and reporting corruption and for investigating and addressing corruption-related issues. The policy document addresses the combatting corruption material issue.

Quality Policy

medmix is active in the design, development and manufacturing of plastic components and finished products, for the Healthcare and Consumer & Industrial business areas, mostly within the business-to-business (B2B) framework but also as legal manufacturer of selected products (applicator systems as medical devices and dispensers as machinery) in selected countries. For the Healthcare business area, medmix is also active as a service provider of specific services such as the filling of dental material and contract manufacturing of combination products.

Product and service quality and customer satisfaction  – for the B2B framework – and product safety and regulatory compliance – for the business as legal manufacturer – represent key drivers and objectives for medmix. This policy responds to the product safety material issue.

Sustainability Policy

Sustainability is engrained in our corporate strategy and embedded in daily business – with the necessary management frameworks, systems and processes. This policy considers the material issues of climate change, human rights, safety, health & wellbeing and sourcing & circularity.

Due diligence

In line with the new requirement of the Swiss Code of Obligations to undertake due diligence into the reasonable suspicion of child labor within medmix and the supply chain, as well as that of the importation and use of conflict minerals, medmix established internal investigative and assessment processes, and performed thorough reviews into these topics.

No suspicious cases were identified.

Presentation of measures adopted

The main milestones established in line with the medmix sustainability strategy are being satisfactorily met:

Further details on these milestones are presented in the following sections.

Presentation of key activities

To achieve these milestones and progress towards the established goals, the following key activities were undertaken during 2023 and their effectiveness determined:

Description of risks

At medmix, risks are assessed regularly as part of the company’s integrated risk management process. The procedure to understand and manage risk is based on a landscape framed by medmix’ objectives and operating environment. medmix Enterprise Risk Management (ERM) involves viewing risk holistically across the organization. Both insurable and non-insurable risks are identified, with the objective to eliminate, mitigate or transfer such risk or prepare to accept them. The medmix ERM embodies the organizational culture of prudent risk-taking and is the process of identifying, assessing and responding to risks, and communicating the outcomes of these analyses in a timely manner. The Executive Committee encourages a strong organizational culture and awareness of risk to ensure that the organization can overcome the factors that inhibit effective risk management.

The following risks and management activities are associated with the medmix identified material issues:

Main performance indicators

medmix defines and determines its main performance indicators with reference to the Global Reporting Initiative (GRI) Consolidated Set of Standards 2021.

New acquisitions are integrated into the medmix performance indicator reporting at the start of the subsequent financial year.

Combatting corruption

People

Planet

Profit